ATAC - Endometrial Sub-protocol

Study identifier:1033IC/0029

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Randomised, Double Blind Trial to Assess the Incidence of Endometrial Changes with Arimidex Alone, Nolvadex Alone, or Arimidex and Nolvadex in Combination, when used as Adjuvant Treatment for Breast Cancer in Postmenopausal Women

Medical condition

Breast Cancer

Phase

Phase 3

Healthy volunteers

No

Study drug

Anastrozole (Arimidex), Tamoxifen (Nolvadex), Nolvadex placebo, Arimidex placebo

Sex

Female

Actual Enrollment

285

Study type

Interventional

Age

45 Years +

Date

Study Start Date: 01 Jun 1997
Primary Completion Date: -
Study Completion Date: 01 Dec 2005

Study design

Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Other

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria